Key result
Thrombopoietin stimulates time- and dose-dependent VEGF release from c-Mpl-expressing megakaryocytic cells and CD34+ progenitors.
Thrombopoietin stimulates VEGF release during megakaryocytic differentiation in c-Mpl-expressing cells.
Thrombopoietin may enhance VEGF release during megakaryopoiesis; leaves open in vivo angiogenesis effects and clinical relevance.
Vascular endothelial growth factor (VEGF) production was analysed in megakaryocytic cell lines and CD34+ haematopoietic progenitors following treatment with thrombopoietin (TPO). In CMK cells TPO caused a time- and dose-dependent increase in the levels of VEGF released into the medium. A similar effect was observed in UT-7/mpl cells transfected with the TPO receptor c-Mpl, but not in parental UT-7 cells. In CD34+ haematopoietic progenitor cell cultures TPO stimulated VEGF mRNA expression and VEGF protein release. Production of VEGF in CD34+ cultures increased with TPO-induced megakaryocytic differentiation, but not with erythroid or myelomonocytic differentiation induced respectively by erythropoietin and granulocyte-macrophage colony-stimulating factor. These results demonstrate that TPO stimulates VEGF release in c-Mpl-expressing cells and suggest that this process is an integral feature of the megakaryocytic differentiation programme.
No takes yet. Share an insight, caveat, or question.
Bobik et al. (1998) studied this question. Thrombopoietin (TPO) vs. Erythropoietin, GM-CSF, or parental UT-7 cells was evaluated on VEGF production and release. Thrombopoietin stimulated a time- and dose-dependent increase in VEGF release from c-Mpl-expressing megakaryocytic cell lines and CD34+ haematopoietic progenitors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: